Mechanistically, BET inhibitors sensitize melanoma cells to sunitinib by inhibiting the BRD4/GDF15 axis and the BRD4/IL6/STAT3/GDF15 axis (Fig. 7g). The gene discussed is STAT3; the disease is melanoma.